

NOTICE TO THE BAR

MULTICOUNTY LITIGATION APPLICATION -- NEW JERSEY STATE COURT LITIGATION ALLEGING USE OF OZEMPIC/RYBELSUS/VICTOZA/WEGOVY PRODUCTS CAUSING GASTROINTESTINAL INJURIES

The Supreme Court has received an application pursuant to Directive #02-19, “Multicounty Litigation Guidelines and Criteria for Designation (Revised),” for Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Novo Nordisk, alleging gastrointestinal injuries as a result of use of Ozempic/Rybelsus/Victoza/Wegovy Products.

The MCL application was submitted by counsel for plaintiffs.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **August 29, 2025** to:

Hon. Michael J. Blee, J.A.D.
Acting Administrative Director of the Courts
Hughes Justice Complex, P.O. Box 037
Trenton, New Jersey 08625-0037
**Attention: MCL Application – Ozempic/Rybelsus/
Victoza/Wegovy (Gastrointestinal Injuries)**

Comments and/or objections may also be submitted by email to Comments.mailbox@njcourts.gov.

A copy of the application submitted to the Court is posted with this Notice on the Judiciary’s Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center <https://www.njcourts.gov/attorneys/multicounty-litigation>.

/s/ Michael J. Blee

Michael J. Blee, J.A.D.
Acting Administrative Director

Dated: July 25, 2025